Cipla is among four companies—the other three being Mylan, Jubilant Life Sciences and Hetero Drugs—who have signed a pact with US-based Gilead for manufacturing of the patented intravenous drug remdesivir NEW DELHI : Cipla plans to work on multiple drugs to find a cure for covid-19 even as the company fine tunes its pact with Gilead Sciences Inc.
on remdesivir, a potential treatment for the respiratory infection, the company’s global chief financial officer Kedar Upadhye said. “We are trying all avenues.
We are attempting to come to the service of patients and try to see that which molecule is more effective. We are trying through all ways.